Preeclampsia Diagnostics Market (Test Type: Blood Test, Urine Test, and Others; Product & Services: Instruments, Reagents & Consumables, and Services)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

According to Nova one advisor, the global Preeclampsia Diagnostics market size was exhibited at USD 1.90 billion in 2022 and is projected to hit around USD 2.90 billion by 2032, growing at a CAGR of 3.80% during the forecast period 2023 to 2032.

Preeclampsia is a special complication of pregnancy. A systolic blood pressure of at least 140 mm Hg or a diastolic blood pressure of at least 90 mm Hg during pregnancy, as well as protein in the urine (proteinuria), both of which appear after week 20 of pregnancy, are required for its diagnosis. If there is only newly developed hypertension, the condition is known as pregnancy-induced hypertension (without proteinuria or other signs of organ affection).

Before the 20th week of pregnancy, some women experience high blood pressure, which is known as chronic hypertension. Preeclampsia and chronic hypertension are the common hypertensive issues of pregnancy. Preeclampsia typically develops at the end of pregnancy with little to no symptoms.

A more severe form of the condition, which can include complications such as eclampsia (fits), cerebral haemorrhage (brain bleeding), pulmonary edoema (fluid collections in the lungs), kidney failure, liver damage, and serious issues with the blood clotting system, develops in about 1 in 100 women with preeclampsia.

Report Scope of the Preeclampsia Diagnostics Market

Surge in Prevalence of Preeclampsia Worldwide

Preeclampsia is a common condition in pregnant women that is becoming more prevalent globally. Preeclampsia diagnostic tests are required due to a rise in blood pressure during pregnancy brought on by changing lifestyles, poor diet, inactivity, alcohol use, and mental stress. Incidence of preeclampsia has grown in the U.S. due to risk factors including advanced maternal age, obesity, and diabetes.

According to the Centers for Disease Control and Prevention, the number of incidences of preeclampsia among childbirth hospitalizations grew from roughly 15% in 2018 to 19% in 2020, affecting at least 1 in 7 deliveries during this time.

Preeclampsia was a documented condition in about one-third of the individuals who died during hospital birth. Preeclampsia was more common (31% more likely) in hospital deliveries for women over 45. This condition was especially prevalent in rural counties (16%) and low-income ZIP codes (16%), as well as in women who gave birth in hospitals in the South (16%) or the Midwest (15%). Therefore, rapid growth in patients with preeclampsia is contributing to the preeclampsia diagnostics market progress during the forecast period.

Increase in Funding for Diagnosis and Treatment of Preeclampsia

The preeclampsia diagnostics industry is primarily driven by heavy investments in preeclampsia research and development by numerous foundations and organizations during the forecast period. For instance, the Preeclampsia Foundation and its Canada-based affiliate, Preeclampsia Foundation Canada, would each give one medical research Vision Grant, up to US$ 20,000, on February 2, 2022, to study preeclampsia and related hypertension disorders of pregnancy.

The Preeclampsia Foundation revealed on January 27, 2022, that MoMMA's Voices, a national alliance of patient advocacy groups and people with "lived experience “(or those who represent them), had received new financing from Merck for Mothers. Merck for Mothers is a global program by Merck that aims to prevent maternal deaths. Hence, increase in funding for preeclampsia research & diagnosis by governments and other organizations is anticipated to propel the preeclampsia diagnostics market development during the forecast period.

Rose in Inclination toward Blood Tests for Accurate Diagnosis of Preeclampsia

The blood test segment dominated the global market of preeclampsia diagnostics with more than 56% share in 2022. Preeclampsia can be accurately predicted by biochemical testing. The tests are extremely helpful in predicting preeclampsia both in the first trimester and in the subsequent trimesters, particularly in cases of an early beginning of the disease.

Services Segment to Hold Major Share of Global Market

Based on product & services, the preeclampsia diagnostics business is divided into instruments, reagents & consumables, and services. The services segment is projected to dominate the global market of preeclampsia diagnostics, and is anticipated to grow at a high CAGR during the forecast period. Services include expenses occurring in the diagnostic laboratory such as rent/EMI on property, staff salary, pathologist’s salary, sample collection, report printing, etc.

Rise in Preference for Hospitals for Diagnosis and Treatment of Severe Preeclampsia

The hospital segment held maximum share of the preeclampsia diagnostics industry in 2022, and is anticipated to grow at a high CAGR from 2023 to 2030. In case of severe preeclampsia, patients are more likely to opt for hospitals for diagnosis and treatment. Patients admitted to hospitals are monitored regularly by taking urine and blood samples. This is estimated to fuel the hospitals segment during the forecast period.

Regional Outlook of Global Preeclampsia Diagnostics Industry

North America accounted for dominating share of 36.9% of the global market in 2022. The market in the region is projected to grow at a CAGR of over 3.60% during the forecast period. Rise in awareness of preeclampsia diagnosis in pregnant women is contributing to the market growth in the region. Several organizations and major players are increasingly focusing on research and development activities to develop advanced products to detect preeclampsia. This is expected to create lucrative opportunities for market players in the North America region during the forecast period.

Asia Pacific was the fastest-growing market in 2022. The market in the region is expected to grow at a CAGR of 5.4% during the forecast period. This can be ascribed to the rise in prevalence of preeclampsia; increase in population of India and China; availability and awareness of preeclampsia tests; and improvement in healthcare infrastructure in the Asia Pacific region. Additionally, increase in awareness about preeclampsia and its treatment is expected to drive the market in the region during the forecast period.

Key Developments

• In July 2022, PerkinElmer, Inc. announced that a placental growth factor (PlGF) measurement using its DELFIA Xpress PlGF 1-2-3TM kit (CE-IVD) and a soluble fms-like tyrosine kinase 1 (sFlt-1)/PlGF ratio using its DELFIA Xpress sFlt-1 kit (CE-IVD), have been included in updated diagnostic guidance issued by the United Kingdom’s National Institute for Health and Care Excellence (NICE) to help diagnose suspected preterm preeclampsia
• In February 2020, Shuwen Biotech Co. Ltd., a China-based leader in developing innovative diagnostics products announced that PerkinElmer, Inc. would distribute Shuwen’s breakthrough diagnostic test for preeclampsia in over 100 countries around the globe, accounting for over 120 million pregnancies annually
• In May 2019, FIGO released new guidelines to combat preeclampsia, and calls for all women to receive first-trimester screening
• In May 2018, Metabolomic Diagnostics secured €2 Mn in European Union funding under the Horizon 2020 SME Instrument, an initiative to accelerate growth in small- and medium-sized companies. The company is all set to support the commercialization of the preterm preeclampsia test, PrePsia.
• In September 2017, Siemens Healthineers announced that it received the CE Mark certification. The company also declared the commercial availability of its versatile Atellica Solution in Europe, the U.S., South America, and Asia. This developed for the upcoming challenges in the testing procedures in the labs.

Some of the prominent players in the Preeclampsia Diagnostics Market include:

• Abbott Laboratories
• ACON Laboratories, Inc.
• ARKRAY, Inc.
• Bio-Rad Laboratories, Inc.
• Cardinal Health
• Danaher Corporation (Beckman Coulter, Inc.)
• Diabetomics, Inc.
• DIRUI Industrial Co., Ltd.
• F. Hoffmann-La Roche Ltd.
• Metabolomic Diagnostics Ltd.
• Sera Prognostics
• Siemens Healthineers AG
• Other prominent players

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Preeclampsia Diagnostics market.

• Test Type
• Blood Test
• Urine Test
• Others
• Product & Services
• Instruments
• Reagents & Consumables
• Services
• End-user
• Hospitals
• Diagnostic Centers
• Others

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Preeclampsia Diagnostics industry analysis from 2023 to 2032 to identify the prevailing Preeclampsia Diagnostics industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Preeclampsia Diagnostics industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Preeclampsia Diagnostics industry trends, key players, market segments, application areas, and market growth strategies.